UTHR241220C440000
- 2.70
- 0.000.00%
United Therapeutics Newsroom
United Therapeutics Insider Sold Shares Worth $2,828,672, According to a Recent SEC Filing
United Therapeutics(UTHR.US) Officer Sells US$3.59 Million in Common Stock
Form 144 | United Therapeutics(UTHR.US) Officer Proposes to Sell 14.53 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 18, $United Therapeutics(UTHR.US)$ Officer Michael Benkowitz intends to sell 40,000 shares of its common stock on Nov 18, with a total market value of approximately $14.53
Earnings Working Against United Therapeutics Corporation's (NASDAQ:UTHR) Share Price
United Therapeutics(UTHR.US) Officer Sells US$9.97 Million in Common Stock
Form 144 | United Therapeutics(UTHR.US) Officer Proposes to Sell 15.31 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 6, $United Therapeutics(UTHR.US)$ Officer Michael Benkowitz intends to sell 40,000 shares of its common stock on Nov 6, with a total market value of approximately $15.31
United Therapeutics(UTHR.US) Director Sells US$3.82 Million in Common Stock
Form 144 | United Therapeutics(UTHR.US) Director Proposes to Sell 3.82 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 5, $United Therapeutics(UTHR.US)$ Director RICHARD GILTNER intends to sell 10,000 shares of its common stock on Nov 5, with a total market value of approximately $3.82
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
United Therapeutics(UTHR.US) Officer Sells US$5.5 Million in Common Stock
Mid-cap Stocks With 'Significant Scope' to Upside – WF
Form 144 | United Therapeutics(UTHR.US) Officer Proposes to Sell 5.5 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 1, $United Therapeutics(UTHR.US)$ Officer MICHAEL I BENKOWITZ REVOCABLE TRUST intends to sell 14,700 shares of its common stock on Nov 1, with a total market value of
Argus Research Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Is Maintained at Buy by Argus Research
Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $432
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $425
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $395 to $600
Express News | United Therapeutics Corp : Leerink Partners Raises Target Price to $390 From $383
United Therapeutics | 8-K: United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
United Therapeutics | 10-Q: Q3 2024 Earnings Report